Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jul 23 · below the Ichimoku cloud · RSI 46 · MACD below its signal
None of the 29 investors followed here reported a position in GDTC in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a GDTC trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 19, 2026 | Choo Chee KongDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 0.98 - 1.02 per share. | 200K | $200.00K |
| May 12, 2026 | Choo Chee KongDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 0.76 per share. | 112K | $84.56K |
Buy / hold / sell counts
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -39.6 | 33.8 | -7.4 | -0.3 | 17.4 | -12.0 | -9.7 | -2.3 | -7.3 | 2.0 | −35.6% | ||
| 2025 | -22.4 | 6.1 | -22.1 | 8.7 | -2.1 | -3.0 | -16.4 | 6.5 | -0.6 | 10.6 | -16.4 | -27.4 | −60.7% |
| 2024 | -27.8 | -43.2 | 8.0 | -2.8 | 2.4 | -3.7 | -13.0 | -18.2 | 6.0 | 53.5 | -2.5 | 44.7 | −30.6% |
| 2023 | -18.5 | 11.7 | 42.6 | -22.4 | 3.7 | 6.6 | -1.1 | 32.8 | +46.3% |